DOCSLIB.ORG
  • Sign Up
  • Log In
  • Upload
  • Sign Up
  • Log In
  • Upload
  • Home
  • »  Tags
  • »  Sulfonylurea

Sulfonylurea

  • Effect of Glucose/Sulfonylurea Interaction on Release of Insulin

    Effect of Glucose/Sulfonylurea Interaction on Release of Insulin

  • Journal of Diabetes and Obesity

    Journal of Diabetes and Obesity

  • Marked Improvement in Glycemic Control with Exenatide on Addition

    Marked Improvement in Glycemic Control with Exenatide on Addition

  • Diabetes in the Elderly: Matching Meds to Needs

    Diabetes in the Elderly: Matching Meds to Needs

  • Liraglutide for the Treatment of Diabetes Mellitus in Japan

    Liraglutide for the Treatment of Diabetes Mellitus in Japan

  • Sulfonylureas

    Sulfonylureas

  • Utah Medicaid Pharmacy and Therapeutics Committee Drug

    Utah Medicaid Pharmacy and Therapeutics Committee Drug

  • (Glyburide) Tablets USP 1.25, 2.5 and 5 Mg DESCRIPTION Diaßeta

    (Glyburide) Tablets USP 1.25, 2.5 and 5 Mg DESCRIPTION Diaßeta

  • Glucagon-Like Peptide-1 Receptor Agonists

    Glucagon-Like Peptide-1 Receptor Agonists

  • Tresiba-Product-Monograph.Pdf

    Tresiba-Product-Monograph.Pdf

  • Association of Body Mass Index with Risk of Major Adverse

    Association of Body Mass Index with Risk of Major Adverse

  • Weekly GLP-1 Receptor Agonist Albiglutide Versus

    Weekly GLP-1 Receptor Agonist Albiglutide Versus

  • Therapeutic Class Overview Dipeptidyl Peptidase-4 (DPP-4) Inhibitors

    Therapeutic Class Overview Dipeptidyl Peptidase-4 (DPP-4) Inhibitors

  • Safety and Effectiveness of Dipeptidyl Peptidase-4 Inhibitors Versus Intermediate-Acting Insulin Or Placebo for Patients with Ty

    Safety and Effectiveness of Dipeptidyl Peptidase-4 Inhibitors Versus Intermediate-Acting Insulin Or Placebo for Patients with Ty

  • Potential of Albiglutide, a Long-Acting GLP-1 Receptor Agonist, in Type 2 Diabetes a Randomized Controlled Trial Exploring Weekly, Biweekly, and Monthly Dosing

    Potential of Albiglutide, a Long-Acting GLP-1 Receptor Agonist, in Type 2 Diabetes a Randomized Controlled Trial Exploring Weekly, Biweekly, and Monthly Dosing

  • FDA Approved Indications1-3

    FDA Approved Indications1-3

  • Sulfonylurea Treatment of Type 2 Diabetic Patients Does Not Reduce the Vasodilator Response to Ischemia

    Sulfonylurea Treatment of Type 2 Diabetic Patients Does Not Reduce the Vasodilator Response to Ischemia

  • Step-Wise Dosing and Titration of Oral Medications for Type 2 Diabetes Last Update 5/3/10

    Step-Wise Dosing and Titration of Oral Medications for Type 2 Diabetes Last Update 5/3/10

Top View
  • Use of Exenatide and Liraglutide in Denmark: a Drug Utilization Study
  • New Drug Evaluation: Albiglutide Month/Year of Review: January
  • Scientific Presentations of Exenatide Data Show Significant
  • Sulfonylurea Overdose in Children
  • Liraglutide (Victoza)
  • American Diabetes Association Treatment Algorithm for Type 2 Diabetes
  • Sulfonylureas Rapidly Cross Phospholipid Bilayer Membranes by a Free-Diffusion Mechanism Frits Kamp,1 Nadeem Kizilbash,1 Barbara E
  • What's Next After Metformin? Focus on Sulphonylurea: Add-On Or Combination Therapy
  • BYETTA (Exenatide) Injection Hemodialysis and Kidney Transplantation
  • Albiglutide (TANZEUM) Drug Monograph
  • GLP-1 Receptor Agonists (Byetta /Victoza ) Step Therapy Criteria
  • Antidiabetic Medication and Risk of Dementia in Patients with Type 2 Diabetes: a Nested Case–Control Study
  • Comparative Safety and Efficacy of Glibenclamide in the Elderly
  • Dipeptidyl Peptidase-4 Inhibitor Compared with Sulfonylurea in Combination with Metformin: Cardiovascular and Renal Outcomes In
  • Rifamycins and Anti-Diabetic Agents: Drug-Drug Interactions
  • Modern Sulfonylureas: Dangerous Matthew C
  • Long-Acting Glucagon-Like Peptide 1 Receptor Agonists a Review of Their Efficacy and Tolerability
  • Comparison of Insulin Degludec/Insulin


© 2024 Docslib.org    Feedback